Corient Private Wealth LP Invests $2.46 Million in LeMaitre Vascular, Inc. $LMAT

Corient Private Wealth LP bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 25,619 shares of the medical instruments supplier’s stock, valued at approximately $2,458,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular in the 2nd quarter worth approximately $47,000. Finally, Quarry LP boosted its holdings in shares of LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 529 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Up 0.8%

Shares of LeMaitre Vascular stock opened at $81.72 on Thursday. The stock has a 50 day moving average of $92.45 and a 200 day moving average of $99.28. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of 28.67, a PEG ratio of 2.34 and a beta of 0.50. LeMaitre Vascular, Inc. has a fifty-two week low of $78.27 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. During the same quarter in the prior year, the firm earned $0.60 EPS. LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s payout ratio is 35.09%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LMAT. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 14th. Wells Fargo & Company cut their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 5th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, LeMaitre Vascular has an average rating of “Hold” and an average target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.